title: 11C-acetate PET for early prediction of sunitinib response in metastatic renal cell carcinoma.
abstract: Sunitinib is an oral multitargeted tyrosine kinase inhibitor with antiangiogenic properties used for treatment of renal cell carcinoma and gastrointestinal stromal tumors at a dose of 50 mg/day consecutively for 4 weeks followed by 2 weeks off per cycle. At present, no data are available on the early prediction of sunitinib response in renal cell carcinoma. We report a clinical case of a patient with metastatic renal cell carcinoma diagnosed with 11C-acetate PET and conventional CT and treated with sunitinib. Partial and complete remission documented by CT was preceded by early functional tumor inhibition shown by 11C-acetate-PET after only 14 days of therapy. This case report highlights some interesting points related to the potential role of a novel non-FDG PET tracer, 11C-acetate, in the early prediction of the response to targeted therapies in metastatic renal cell carcinoma.
authors.affiliation: Institute of Hematology and Medical Oncology "L. & A. Seragnoli", Sant'Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy. alessandramaleddu@gmail.com
authors.forename: Alessandra
authors.initials: A
authors.lastname: Maleddu
authors.forename: Maria A
authors.initials: MA
authors.lastname: Pantaleo
authors.forename: Paolo
authors.initials: P
authors.lastname: Castellucci
authors.forename: Maria
authors.initials: M
authors.lastname: Astorino
authors.forename: Cristina
authors.initials: C
authors.lastname: Nanni
authors.forename: Margherita
authors.initials: M
authors.lastname: Nannini
authors.forename: Fiorenza
authors.initials: F
authors.lastname: Busato
authors.forename: Monica
authors.initials: M
authors.lastname: Di Battista
authors.forename: Mohsen
authors.initials: M
authors.lastname: Farsad
authors.forename: Filippo
authors.initials: F
authors.lastname: Lodi
authors.forename: Stefano
authors.initials: S
authors.lastname: Boschi
authors.forename: Stefano
authors.initials: S
authors.lastname: Fanti
authors.forename: Guido
authors.initials: G
authors.lastname: Biasco
mesh_terms: D000310:Adrenal Gland Neoplasms / Q000556:secondary / Q000601:surgery; D000315:Adrenalectomy; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002250:Carbon Radioisotopes; D002292:Carcinoma, Renal Cell / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000556:secondary* / Q000601:surgery; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000473:pathology* / Q000601:surgery; D008113:Liver Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000556:secondary; D009392:Nephrectomy; D010190:Pancreatic Neoplasms / Q000556:secondary / Q000601:surgery; D016577:Pancreaticoduodenectomy; D049268:Positron-Emission Tomography / Q000379:methods; D011237:Predictive Value of Tests; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011758:Pyrroles / Q000627:therapeutic use*; D000077210:Sunitinib; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D002250:Carbon Radioisotopes; D007211:Indoles; D047428:Protein Kinase Inhibitors; D011758:Pyrroles; D019788:Fluorodeoxyglucose F18; D000077210:Sunitinib